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Figure 1. Stress strain diagram of Fibrin gel (left) and the injectable plaster
(right). The ﬁbrin gel does not show any up build of forces and is poorly
adhering to the defect surface. This in contrast to the injectable plaster.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S151Conclusions: Our results show that a transient (24 hour) exposure of
cartilage-to-cartilage repair models to Sprifermin improves integration
strength and matrix deposition at the interface (as evidenced by con-
trast-enhanced mCT showing a more uniform attenuation by increase in
GAG-containing proteoglycans). In this study, one 24 hour admin-
istrationweekly for 4 weeks leads to an overall better outcome than one
24 hour treatment over one month. This study represents for the ﬁrst
time a biologic (and in particular an FGF) has improved the integration
of cartilage surfaces in a clinically relevant repair model. The ﬁndings
implicates Sprifermin potential usefulness in surgical procedures such
as OATS and in tissue engineering approaches where cartilage like
biomaterials will be required to successfully integrate with native car-
tilage in order to achieve clinical success.
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CHONDROGENESIS FROM HUMAN INDUCED PLURIPOTENT STEM
CELLS: EPIGENETIC CAUSES OF LOW HYPERTROPHY INDUCTION
S. Park, J.-Y. Ko, G.-I. Im. Dongguk Univ. Ilsan Hosp., Goyang, REPUBLIC OF
KOREA
Purpose: The purpose of this studywas to test the in vitro chondrogenic
potential and in vivo capacity for cartilage regeneration of human iPS
(hiPS) cells.
Methods: Cell culture and differentiation of EB We used the hiPSC line
(SBI, cat# SC802A-1) generated by direct delivery of four proteins fused
to a cell penetrating peptide. hiPSCs were passaged to Matrigel-coated
polystyrene plates and cultured in the deﬁned mTeSR1 medium. To
inducemesenchymal differentiation, embryoid bodies were formed and
cultured in suspension for 11 days with hESC growth medium in low-
attachment culture dishes.
Chondrogenic differentiation: Chondrocytic differentiation was
induced by trypsinizing EB to a single cell suspension, diluting cells to a
ﬁnal concentration of 5x105 cells/ml and forming micromass pellets by
centrifugation. Micromass pellets were cultured in 15-ml conical tubes
for 21 days using DMEM/F12 medium,of supplemented with 1% ITS
(insulin-transferrin-selenium), 10-7 M dexamethasone, 50 mM ascor-
bate-2-phosphate, 50 mM L-proline, 1 mM sodium pyruvate and 10ng/
ml TGF-b3.
Analysis for chondrogenic differentiation: After 21 days of in vitro
culture, pellets were analyzed for DNA contents, GAG amount, the
expression of chondrogenic markers, and the methylation status.
Transplantation:The hiPS-pellets or alginate-hiPSCs constructs were
implanted in the osteochondral defect model rat. The rats received daily
injections of cyclosporin A to suppress immune responses in rats. After
6 weeks, the rats were sacriﬁced.
Results: Mesodermal markers increased in EB while undifferentiated ES
markersdisappeared.After 21days of chondrogenic culture inmicromass
pellets, GAG analysis showed that proteoglycan production was sig-
niﬁcantly greater in chondrogenic pellets than in undifferentiated hiPSCs
and EBs. Safranin-O staining demonstrated that the cells in chondrogenic
pellets took on the appearance of immature chondrocytes and secreted
extracellular matrix. The chondrogenic marker gene and protein
expression increased after 21days of pellet culture. The chondrogenic
pellets derived from hiPSCs have very low expression of hypertrophic or
osteogenicmarkers. Also,methylationwas increased in hiPSCs compared
to hBMSCs in the COL10A1promoter. This result suggested the epigenetic
disparity is the cause of the difference in hypertrophy.
When hiPSCs in either pellet state or in alginate hydrogel were
implanted in the osteochondral defects created on the patellar groove of
immunosuppressed rats, the defects implanted with chondro-induced
hiPSCs showed a signiﬁcantly better quality of cartilage repair than the
control defects.
Conclusions: In conclusion, this study provides a proof-of-principle
strategy for using hiPSCs as a cell source for cartilage tissue engineering.
While successful in vitro induction of chondrogenesis with improved
biochemical characteristics were obtained from hiPS cells, the working
mechanisms in the implantation of hiPS cells and strategies for further
improvement of in vivo cartilage repair with hiPS cells should be
investigated in future studies.
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INJECTABLE HYDROGELS FOR CARTILAGE REPAIR
S. Both, R. Wang, P. Dijkstra, M. Karperien. Univ. of Twente, Enschede,
NetherlandsPurpose: To create an injectable hydrogel that can be used to
plaster eroded cartilage surfaces and / or to ﬁll up focal cartilage
defects in a minimally invasive arthroscopic procedure. The plaster
should protect the damaged cartilage surface against further car-
tilage erosion and possess an optimized environment for cartilage
regeneration.
Methods: Over the last years we have develop an injectable plaster by
introducing hydroxyphenyl groups in the backbone of naturally
occurring polymers such as dextran, hyaluronic acid and heparin
which resemble or normally reside in the extracellular cartilage
matrix. This renders an injectable hydrogel which gelates in an
enzymatic peroxidase mediated reaction initiated by non-toxic con-
centrations of H2O2.
From in vitro testing we know that our plaster is biocompatible and that
it supports cartilage formation of incorporated primary chondrocytes,
mesenchymal stromal cells or combinations of both. To further improve
our injectable plaster we have introduced several cell attracting, carti-
lage-mimicking and/or chondrogenesis stimulating elements and
studied cartilage formation. The adhesive properties of the injectable
plaster was compared to clinically used ﬁbrin glue in a customized set
up. Finally pilot studies were performed in fresh horse cadavers to test
whether the plaster could be applied in focal cartilage defects in an
arthroscopic procedure. The repaired joint wasmanually ﬂexed to study
the plaster’s resistance to force.
Results: The incorporation of heparin, hyaluronic acid and chon-
droitin sulphate in a dextran based hydrogel resulted in a che-
moattractant plaster facilitating ingrowth of chondrocytes and
mesenchymal stromal cells. When chondrocytes were incorporated
the addition of these elements potently stimulated neocartilage
formation by encapsulated chondrocytes based on histological
analysis and gene expression of typical cartilage markers like
COL2A, SOX9 and AGC. The binding of the hydrogel to surface of
the defect is important for future clinical applications. Therefore
we compared our hydrogel to clinically used ﬁbrin gel and found
that gel ﬁxation of the injectable plaster is at least 1 order of
magnitude stronger than the gluing properties of ﬁbrin gel (Fig-
ure 1). In addition, rheology showed that the injectable plaster has
improved mechanical properties compared to ﬁbrin gel. Next we
tested our injectable plaster in a minimally invasive surgical pro-
cedure. Thus the gel was injected via arthroscopic procedure in a
full thickness defect in the joint of a horse. Subsequent the knee of
the horse was ﬂexed manually to test the injectable plaster which
remained in its place (Figure 2). Since this was a success we are
currently planning our next in vivo study in which the horses will
be followed in time to see how the plaster reacts in a full load
bearing joint.
Conclusions: We have developed an injectable hydrogel that gelates in
situ using a biocompatible enzymatic cross linking reaction and we
have shown that this hydrogel is chemoattractant for chondrocyte
progenitors and mesenchymal stem cells. We found that gel ﬁxation of
the injectable plaster is stronger than the gluing properties of clinically
used ﬁbrin gel. Next we demonstrated that this hydrogel can be applied
in a minimally invasive arthroscopic procedure in a horse knee and
strongly binds to cartilage and subchondral bone by covalent bonding of
the hydrogel to the native tissue.
We are nowperforming experiments in live animals to test the potential
of these injectable plasters to facilitate regeneration of damaged carti-
lage surfaces.
